AJMC Staff
Articles
Nivolumab, Alone or With Ipilimumab, Met the Disease Control Rate in Malignant Pleural Mesothelioma
In a late-breaking abstract at the 2017 American Society of Clinical Oncology Annual Meeting, researchers presented an interim analysis of a randomized phase 2 trial of second- or third-line nivolumab, with or without ipilimumab, in patients with second- or third-line malignant pleural mesothelioma.
Three Months of Oxaliplatin-Based Adjuvant Therapy Noninferior to 6 Months in Stage III Colon Cancer
The International Duration Evaluation of Adjuvant chemotherapy (IDEA) collaboration found evidence to support the noninferiority of 3 versus 6 months oxaliplatin-based adjuvant therapy for capecitabine plus oxaliplatin for patients with stage III colon cancer.
Fas Biomarker Can Predict Response to Second-Line Therapy for Advanced Soft Tissue Sarcoma
In a study performed by the Grupo Español de Investigación en Sarcomas, Fas biomarker detection showed value in predicting progression-free and overall survival after trabectedin administration to patients with advanced soft tissue sarcoma.
Trabectedin and Lurbinectedin Effective in BRCA2-Associated Metastatic Breast Cancer
An interim analysis of two phase 2 trials, reported in a poster session at the 2017 American Society of Clinical Oncology Annual Meeting, has found that trabectedin and lurinectedin demonstrated remarkable activity as single agents in BRCA2-associated metastatic breast cancer.
Alectinib May Be a New Standard of Care for Treatment-Naïve ALK-Positive NSCLC
A late-breaking abstract at the 2017 American Society of Clinical Oncology Annual Meeting showed that alectinib demonstrates efficacy and favorable tolerability compared with crizotinib in the primary results of the global phase 3 ALEX study in patients with treatment-naïve advanced anaplastic lymphoma kinase (ALK)-positive non—small cell lung cancer (NSCLC).
Dacomitinib a New First-Line Option for Advanced EGFR Mutation—Positive NSCLC
ARCHER 1050, the first phase 3 head-to-head study of epithelial growth factor receptor (EGFR) tyrosine kinase inhibition, has produced results that demonstrate statistically significant and clinically meaningful improvement with dacomitinib compared with gefitinib (Iressa) as first-line therapy for non—small cell lung cancer (NSCLC) with EGFR-activating mutations.
